Topical BPC-157 for Skin Healing and Wound Repair

Topical BPC-157, usually sold as a cream or gel, is a peptide preparation applied directly to the skin with the goal of accelerating wound healing or reducing inflammation at the site. Animal studies, primarily in mice and rats, consistently show that BPC-157 in cream form speeds up burn healing, increases new blood vessel formation, and improves collagen deposition. The catch is that virtually all of this evidence comes from rodent experiments, and only a handful of small human studies on BPC-157 exist in any form, let alone topical. That gap between promising preclinical results and a near-total absence of human data is the defining feature of the BPC-157 story right now.

What BPC-157 Actually Is

BPC-157 is a synthetic peptide made of 15 amino acids. It is derived from a larger protein found naturally in human gastric juice, a substance researchers identified and named Body Protection Compound, or BPC. The parent protein has a molecular weight of about 40,000 daltons, and BPC-157 is the fragment thought to be responsible for its biological activity.¹ Because the peptide originates from the gut, early research focused on its effects on stomach ulcers and intestinal damage. But over the past two decades, the research has branched into wound healing, tendon repair, ligament injuries, and more, with investigators testing oral, injected, and topical delivery routes.

One reason BPC-157 attracted attention is its unusual stability. Most peptides degrade quickly in the body or on the skin. BPC-157 resists breakdown in stomach acid and remains active in various formulations, which makes it a plausible candidate for topical products. It has been used in early-stage clinical trials for ulcerative colitis and multiple sclerosis under the pharmaceutical designation PL-14736, and in those trials, no toxicity was reported.² That stability and apparent safety profile are part of why the peptide has generated so much grassroots interest, particularly among athletes and biohackers looking for faster recovery.

What the Animal Studies Show for Topical Use

The most direct evidence for topical BPC-157 comes from burn-wound studies in mice. In the key experiment, researchers applied a thin layer of BPC-157 cream to burn injuries caused by direct flame exposure. The cream was made by dissolving BPC-157 in distilled water and mixing it into a commercial neutral cream base. Compared with untreated mice and mice given the cream base alone, the BPC-157 group showed less swelling, fewer inflammatory cells, and less tissue death throughout the experiment. New blood vessels formed more readily, and the structural fibers that make up the deeper layers of skin, reticulin and collagen, developed faster. Hair follicles were better preserved. After two weeks, the BPC-157-treated mice had completely reversed the poor skin regrowth seen in controls.³

One intriguing detail from that study is dose range. Researchers tested the cream at concentrations spanning a thousand-fold difference, and healing improvements appeared even at the lowest doses. This suggests the peptide is biologically active in very small amounts when applied to wounded skin, though what that means for an ideal human dose remains completely unknown.

A separate study examined alkali burns, a different and particularly damaging type of chemical injury. When BPC-157 was applied to alkali-burned skin in a rodent model, histological examination showed better formation of new tissue, faster regrowth of the outer skin layer, improved remodeling of the underlying dermis, and greater collagen deposition compared to control groups at 18 days after wounding.⁴ A consistent pattern emerges across these experiments: BPC-157 seems to push each stage of wound healing forward, from the initial inflammatory response through tissue rebuilding and final remodeling.

How BPC-157 Promotes Healing at the Tissue Level

The leading explanation for how BPC-157 works centers on blood vessel growth. Healing tissue needs new blood vessels to deliver oxygen and nutrients to the repair site, and BPC-157 appears to stimulate this process by increasing the expression of vascular endothelial growth factor, or VEGF, a protein that signals blood vessel formation. In a study examining both cell cultures and live animals with crushed or cut muscle and tendon tissue, researchers found that BPC-157 did not directly trigger blood vessel growth in isolated cells. Instead, its effect appeared only in living tissue, where it upregulated VEGF and produced what the authors called “adequately modulated angiogenesis,” meaning the blood vessel growth was proportional to the healing need rather than excessive.⁵

That distinction matters. Uncontrolled blood vessel growth can be a problem, contributing to scar tissue or, in theory, feeding tumors. The fact that BPC-157’s angiogenic effect showed up only in the context of active healing, and appeared well-regulated rather than indiscriminate, is part of why researchers have been cautiously optimistic. A 2025 narrative review described BPC-157 as activating the VEGFR2 receptor and the nitric oxide synthesis pathway, promoting not just blood vessel formation but also fibroblast activity, which is the cell type responsible for laying down new connective tissue.⁶

Counteracting Steroid-Impaired Healing

One of the more practically interesting findings involves corticosteroids. If you have ever used a steroid cream or taken oral steroids, you know that one well-documented side effect is slower wound healing. Steroids suppress the immune and inflammatory responses that kickstart tissue repair, which is useful for controlling inflammation but problematic when you actually need to heal. In a mouse burn model, researchers tested whether topical BPC-157 cream could overcome this problem. Mice given the corticosteroid 6-alpha-methylprednisolone had measurably worse burn healing. When BPC-157 cream was applied on top of steroid treatment, healing improved on both microscopic examination and mechanical strength testing, effectively counteracting the steroid-induced impairment.⁷

This finding is relevant to a common real-world scenario. People with inflammatory skin conditions often use topical corticosteroids long-term and then struggle with delayed healing of any cuts, scrapes, or surgical wounds. If BPC-157 can reverse that delay, even partially, it would fill a genuine clinical gap. But the data so far only covers mice, and nobody has tested this interaction in human skin.

Beyond Skin Burns and Wounds

Topical BPC-157 has also been tested on connective tissue injuries. In a rat study on ligament damage, researchers cut the medial collateral ligament (the ligament on the inner side of the knee) and applied BPC-157 as a thin cream layer at the injury site daily. The treated rats showed consistent improvements in function, mechanical strength, and tissue structure compared with controls.⁸ The same study also tested injected BPC-157 and found that both topical and injected routes produced healing benefits, though the mechanisms of action for a topical cream reaching a deep ligament are not entirely clear.

A narrative review from the Yale Journal of Biology and Medicine confirmed that BPC-157 has been investigated across oral, topical, and injected routes for its effects on tendons, ligaments, skeletal muscle, and bone in small animal models, and that it has shown promise across all of these tissues.⁹ The breadth of tissues responding to BPC-157 is unusual and has raised questions about whether the peptide acts through some fundamental repair pathway rather than a tissue-specific one.

A study on persistent skin wounds and gastric ulcers in rats found that BPC-157 showed greater healing potential than standard treatments, and that it was effective when given in drinking water or applied locally, including in difficult-to-heal scenarios involving fistulas that had been worsened by steroid use.¹⁰

Formulation and Delivery Challenges

How you get a peptide into the skin is not a trivial problem. Peptides are relatively large molecules compared with typical drug compounds, and the outer layer of skin (the stratum corneum) is specifically designed to keep large molecules out. The original mouse studies used a simple approach: dissolving BPC-157 in distilled water and mixing it into a commercially available neutral cream base. That worked in the context of burn wounds, where the skin barrier was already compromised.

For intact skin or less severe injuries, researchers are exploring more sophisticated delivery methods. A recent study developed a chitosan-based hydrogel loaded with BPC-157. The hydrogel not only served as a carrier for the peptide but also added its own benefits: the BPC-157 chitosan hydrogel demonstrated antibacterial activity, inhibiting the growth of common wound-infecting bacteria by roughly 46% for E. coli and 65% for Staphylococcus aureus.¹¹ That antibacterial property could be meaningful for wound care, since infection is one of the main obstacles to healing.

The challenge for any commercial topical BPC-157 product is proving that the peptide actually penetrates the skin in meaningful amounts. The animal studies that used cream on open burn wounds had the advantage of a disrupted skin barrier. Whether a cream or gel applied to intact skin, a closed surgical incision, or a healing tattoo can deliver enough peptide to the target tissue is genuinely unknown. Products marketed online generally do not provide absorption data.

The Human Evidence Problem

This is where the optimistic picture gets complicated. A 2025 systematic review of BPC-157 in orthopedic and sports medicine found 36 studies in the literature. Of those, 35 were preclinical, meaning they were conducted in animals or cell cultures. Only a single clinical study was identified.¹² A separate narrative review noted that across all applications, only three small pilot studies have examined BPC-157 in humans at all, and those looked at knee pain (injected, not topical), interstitial cystitis, and intravenous safety.¹³ No published human trial has tested topical BPC-157 for wound healing.

A review covering both BPC-157 and the copper peptide GHK-Cu confirmed the same gap: preclinical studies show BPC-157 promotes healing in skin, tendon, muscle, and bone, but comprehensive randomized controlled trials are absent.¹⁴ The evidence that exists is strongly positive but almost entirely non-human. That is a common early stage for promising compounds, but it means anyone using topical BPC-157 right now is essentially running a personal experiment based on rodent data.

Why the delay in human trials? Part of the answer is regulatory. BPC-157 is a synthetic peptide that does not fit neatly into existing drug categories. Getting it through the approval process for clinical trials requires significant investment, and the compound is not patentable in a way that would give a pharmaceutical company exclusive marketing rights. That economic reality has slowed formal clinical development even as consumer demand has accelerated.

Safety Profile and Open Questions

One genuinely reassuring aspect of the BPC-157 literature is the absence of reported toxicity in animal studies. Preclinical safety assessments across multiple organ systems have not found adverse effects, and in the early human trials for other conditions, no toxicity was observed even at doses where researchers tried to establish a lethal threshold and could not.¹⁵ That said, the same systematic review found no clinical safety data specifically for BPC-157, meaning the safety profile in humans is based on a very small number of subjects.

For topical use specifically, the safety question is somewhat simpler than for injections or oral dosing. A cream applied to the skin surface generally poses lower systemic risk because less of the compound enters the bloodstream. The main theoretical concerns would be local skin reactions (irritation, allergic response) and the effects of promoting blood vessel growth in areas where that might not be desirable. Anyone with a history of abnormal scarring, active skin cancer, or conditions involving excessive blood vessel growth should be cautious, though no specific adverse events in these populations have been reported in the literature, largely because these populations have never been studied.

What You Can Actually Buy

Topical BPC-157 products are widely available online, sold as creams, gels, and serums by compounding pharmacies, supplement companies, and peptide vendors. The quality control situation is concerning. BPC-157 is not approved by the FDA as a drug, dietary supplement, or cosmetic ingredient. Products sold online are not subject to the manufacturing standards, purity testing, or labeling accuracy requirements that would apply to approved medications. Independent testing of commercially available peptide products has sometimes found degraded peptides, incorrect dosages, or contamination.

If you are considering a topical BPC-157 product, the most reliable sourcing option is a licensed compounding pharmacy that produces the cream or gel under pharmacy-grade conditions. These pharmacies operate under state oversight and follow United States Pharmacopeia (USP) standards for sterile and non-sterile compounding. Products from unregulated online peptide vendors are a gamble in terms of what is actually in the bottle.

Concentration also varies wildly between products, and there is no established human dose for topical BPC-157. The mouse studies used formulations in the range of micrograms of peptide per gram of cream, but translating animal doses to human doses is not straightforward, and commercial products rarely disclose their BPC-157 concentration in a way that maps onto the research literature. Some products advertise high peptide content without independent verification.

Where BPC-157 Fits Among Other Wound-Healing Peptides

BPC-157 is not the only peptide being explored for topical wound healing. GHK-Cu, a copper-binding peptide, has its own body of research showing enhanced collagen and elastin production, blood vessel growth, and fibroblast migration.¹⁶ GHK-Cu has a slight edge in terms of cosmetic-industry adoption. It appears in commercially available skincare products and has been tested in small human trials for skin quality. BPC-157, by contrast, has stronger preclinical wound-healing data but virtually no human cosmetic data.

The two peptides work through partially overlapping but distinct mechanisms. BPC-157 is more closely associated with VEGF-driven blood vessel formation and broad tissue repair signaling, while GHK-Cu has a more established role in extracellular matrix remodeling, the process of rebuilding the structural scaffolding of skin. Some online vendors sell formulations combining both peptides, though no published study has tested whether combining them produces additive or synergistic effects. The theoretical case for combining them is reasonable, since they target different parts of the healing cascade, but theory and evidence are not the same thing.

Another difference worth noting is regulatory trajectory. GHK-Cu has been incorporated into cosmeceutical products that fall under cosmetic regulations rather than drug regulations, which is an easier path to market. BPC-157’s identity as a gastric peptide fragment with drug-like biological activity makes it harder to classify as a cosmetic ingredient, which has kept it in a regulatory gray zone that complicates both research and commercialization.